393 related articles for article (PubMed ID: 33010460)
1. Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors.
Shaverdian N; Beattie J; Thor M; Offin M; Shepherd AF; Gelblum DY; Wu AJ; Simone CB; Hellmann MD; Chaft JE; Rimner A; Gomez DR
Ann Oncol; 2020 Dec; 31(12):1719-1724. PubMed ID: 33010460
[TBL] [Abstract][Full Text] [Related]
2. Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors.
Bi J; Qian J; Yang D; Sun L; Lin S; Li Y; Xue X; Nie T; Verma V; Han G
Front Immunol; 2021; 12():828858. PubMed ID: 35095930
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Pneumonitis Profile of Thoracic Radiotherapy Followed by Immune Checkpoint Inhibitor and Risk Factors for Radiation Recall Pneumonitis in Lung Cancer.
Lu X; Wang J; Zhang T; Zhou Z; Deng L; Wang X; Wang W; Liu W; Tang W; Wang Z; Wang J; Jiang W; Bi N; Wang L
Front Immunol; 2022; 13():918787. PubMed ID: 35795657
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric predictors of radiation pneumonitis in patients with prior immunotherapy exposure: A multi-institutional analysis.
Bi J; Meng R; Yang D; Li Y; Cai J; Zhang L; Qian J; Xue X; Hu S; Yuan Z; Verma V; Bi N; Han G
Radiother Oncol; 2024 Jan; 190():110040. PubMed ID: 38042497
[TBL] [Abstract][Full Text] [Related]
5. Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer.
Hayashi K; Yamamoto N; Karube M; Nakajima M; Matsufuji N; Tsuji H; Ogawa K; Kamada T
Radiat Oncol; 2017 May; 12(1):91. PubMed ID: 28558766
[TBL] [Abstract][Full Text] [Related]
6. The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation.
Ren C; Ji T; Liu T; Dang J; Li G
Radiat Oncol; 2018 Apr; 13(1):69. PubMed ID: 29661254
[TBL] [Abstract][Full Text] [Related]
7. Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy.
Jia W; Gao Q; Wang M; Li J; Jing W; Yu J; Zhu H
Radiat Oncol; 2021 Feb; 16(1):41. PubMed ID: 33622352
[TBL] [Abstract][Full Text] [Related]
8. Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study.
Jang JY; Kim SS; Song SY; Kim YJ; Kim SW; Choi EK
Radiat Oncol; 2021 Dec; 16(1):231. PubMed ID: 34863244
[TBL] [Abstract][Full Text] [Related]
9. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis.
Claude L; Pérol D; Ginestet C; Falchero L; Arpin D; Vincent M; Martel I; Hominal S; Cordier JF; Carrie C
Radiother Oncol; 2004 May; 71(2):175-81. PubMed ID: 15110451
[TBL] [Abstract][Full Text] [Related]
10. Distinguishing immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis by CT radiomics features in non-small cell lung cancer.
Peiliang Wang MD; Yikun Li MM; Mengyu Zhao MM; Jinming Yu MD; Feifei Teng MD
Int Immunopharmacol; 2024 Feb; 128():111489. PubMed ID: 38266450
[TBL] [Abstract][Full Text] [Related]
11. Dose-volume analysis of radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel.
Barriger RB; Fakiris AJ; Hanna N; Yu M; Mantravadi P; McGarry RC
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1381-6. PubMed ID: 20231061
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary dose-volume predictors of radiation pneumonitis following stereotactic body radiation therapy.
Harder EM; Park HS; Chen ZJ; Decker RH
Pract Radiat Oncol; 2016; 6(6):e353-e359. PubMed ID: 27156424
[TBL] [Abstract][Full Text] [Related]
13. Study of the predictors for radiation pneumonitis in patient with non-small cell lung cancer received radiotherapy after pneumonectomy.
Yu JH; Wang CL; Liu Y; Wang JM; Lv CX; Liu J; Zhang Q; Fu XL; Cai XW
Cancer Radiother; 2021 Jun; 25(4):323-329. PubMed ID: 33446419
[TBL] [Abstract][Full Text] [Related]
14. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
[TBL] [Abstract][Full Text] [Related]
15. [Low dose volume histogram analysis of the lungs in prediction of acute radiation pneumonitis in patients with esophageal cancer treated with three-dimensional conformal radiotherapy].
Shen WB; Zhu SC; Gao HM; Li YM; Liu ZK; Li J; Su JW; Wan J
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):45-9. PubMed ID: 23648300
[TBL] [Abstract][Full Text] [Related]
16. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy.
Liu H; Zhang X; Vinogradskiy YY; Swisher SG; Komaki R; Chang JY
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):1017-23. PubMed ID: 22543216
[TBL] [Abstract][Full Text] [Related]
17. Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies.
Chen X; Sheikh K; Nakajima E; Lin CT; Lee J; Hu C; Hales RK; Forde PM; Naidoo J; Voong KR
Oncologist; 2021 Oct; 26(10):e1822-e1832. PubMed ID: 34251728
[TBL] [Abstract][Full Text] [Related]
18. Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis.
Katsui K; Ogata T; Watanabe K; Katayama N; Soh J; Kuroda M; Kiura K; Maeda Y; Toyooka S; Kanazawa S
BMC Cancer; 2019 Nov; 19(1):1144. PubMed ID: 31771538
[TBL] [Abstract][Full Text] [Related]
19. Incidence and risk factors for pneumonitis among patients with lung cancer who received immune checkpoint inhibitors after palliative thoracic radiotherapy.
Saito S; Abe T; Iino M; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Yamaguchi O; Kaira K; Kagamu H; Noda SE; Kato S
J Radiat Res; 2021 Jul; 62(4):669-675. PubMed ID: 34121123
[TBL] [Abstract][Full Text] [Related]
20. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
